Cytek Biosciences, Inc.
CTKB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 14.7% | 10% | -27.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 52.7% | 52.3% | 48.6% | 58.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -17.6% | -23.3% | -36.1% | 5.2% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | $0 |
| Tax Expense | -$0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -10.5% | -12.2% | -27.5% | 16.8% |
| EPS | -0.04 | -0.044 | -0.09 | 0.074 |
| % Growth | 9.1% | 51.1% | -222.3% | – |
| EPS Diluted | -0.04 | -0.044 | -0.09 | 0.073 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -8.1% | -7.4% | -19.5% | -4.3% |